Dec. 15 (Bloomberg) -- Biotechnology companies with cash and promising products can spurn offers from drugmakers hunting for bargains during the global financial crisis and ultimately command higher premiums than their cash-starved peers.
Dec. 15 (Bloomberg) -- Biotechnology companies with cash and promising products can spurn offers from drugmakers hunting for bargains during the global financial crisis and ultimately command higher premiums than their cash-starved peers.
